Selected research
Market Structure
Global Fidaxomicin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Fidaxomicin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Fidaxomicin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Fidaxomicin include Merck, Livzon Group, Tecoland, Rochem, Optimer Pharmaceuticals, Olon, BrightGene Bio-Medical Technology and Astellas, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Fidaxomicin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Fidaxomicin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Fidaxomicin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Fidaxomicin market size, projected growth trends, production technologies, key applications, and end-use industries.
Fidaxomicin Segment by Company
Merck
Livzon Group
Tecoland
Rochem
Optimer Pharmaceuticals
Olon
BrightGene Bio-Medical Technology
Astellas
Fidaxomicin Segment by Type
Purity:90%
Purity:95%
Others
Fidaxomicin Segment by Application
Hospital
Retail Pharmacies
Fidaxomicin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fidaxomicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fidaxomicin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fidaxomicin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Fidaxomicin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fidaxomicin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Fidaxomicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Fidaxomicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Purity:90%
- Purity:95%
- Others
Applications
- Hospital
- Retail Pharmacies
Companies covered
- Merck
- Livzon Group
- Tecoland
- Rochem
- Optimer Pharmaceuticals
- Olon
- BrightGene Bio-Medical Technology
- Astellas
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Fidaxomicin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Fidaxomicin Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Fidaxomicin Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Fidaxomicin Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Fidaxomicin Market Dynamics
- 2.1 Fidaxomicin Industry Trends
- 2.2 Fidaxomicin Industry Drivers
- 2.3 Fidaxomicin Industry Opportunities and Challenges
- 2.4 Fidaxomicin Industry Restraints
3 Fidaxomicin Market by Manufacturers
- 3.1 Global Fidaxomicin Revenue by Manufacturers (2021-2026)
- 3.2 Global Fidaxomicin Sales by Manufacturers (2021-2026)
- 3.3 Global Fidaxomicin Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Fidaxomicin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Fidaxomicin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Fidaxomicin Manufacturers, Product Type & Application
- 3.7 Global Fidaxomicin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Fidaxomicin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Fidaxomicin Players Market Share by Revenue in 2025
- 3.8.3 2025 Fidaxomicin Tier 1, Tier 2, and Tier 3
4 Fidaxomicin Market by Type
- 4.1 Fidaxomicin Type Introduction
- 4.1.1 Purity:90%
- 4.1.2 Purity:95%
- 4.1.3 Others
- 4.2 Global Fidaxomicin Sales by Type
- 4.2.1 Global Fidaxomicin Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Fidaxomicin Sales by Type (2021-2032)
- 4.2.3 Global Fidaxomicin Sales Market Share by Type (2021-2032)
- 4.3 Global Fidaxomicin Revenue by Type
- 4.3.1 Global Fidaxomicin Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Fidaxomicin Revenue by Type (2021-2032)
- 4.3.3 Global Fidaxomicin Revenue Market Share by Type (2021-2032)
5 Fidaxomicin Market by Application
- 5.1 Fidaxomicin Application Introduction
- 5.1.1 Hospital
- 5.1.2 Retail Pharmacies
- 5.2 Global Fidaxomicin Sales by Application
- 5.2.1 Global Fidaxomicin Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Fidaxomicin Sales by Application (2021-2032)
- 5.2.3 Global Fidaxomicin Sales Market Share by Application (2021-2032)
- 5.3 Global Fidaxomicin Revenue by Application
- 5.3.1 Global Fidaxomicin Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Fidaxomicin Revenue by Application (2021-2032)
- 5.3.3 Global Fidaxomicin Revenue Market Share by Application (2021-2032)
6 Global Fidaxomicin Sales by Region
- 6.1 Global Fidaxomicin Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Fidaxomicin Sales by Region (2021-2032)
- 6.2.1 Global Fidaxomicin Sales by Region (2021-2026)
- 6.2.2 Global Fidaxomicin Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Fidaxomicin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Fidaxomicin Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Fidaxomicin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Fidaxomicin Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Fidaxomicin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Fidaxomicin Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Fidaxomicin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Fidaxomicin Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Fidaxomicin Revenue by Region
- 7.1 Global Fidaxomicin Revenue by Region
- 7.1.1 Global Fidaxomicin Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Fidaxomicin Revenue by Region (2021-2026)
- 7.1.3 Global Fidaxomicin Revenue by Region (2027-2032)
- 7.1.4 Global Fidaxomicin Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Fidaxomicin Revenue (2021-2032)
- 7.2.2 North America Fidaxomicin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Fidaxomicin Revenue (2021-2032)
- 7.3.2 Europe Fidaxomicin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Fidaxomicin Revenue (2021-2032)
- 7.4.2 Asia-Pacific Fidaxomicin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Fidaxomicin Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Fidaxomicin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Merck
- 8.1.1 Merck Company Information
- 8.1.2 Merck Business Overview
- 8.1.3 Merck Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Merck Fidaxomicin Product Portfolio
- 8.1.5 Merck Recent Developments
- 8.2 Livzon Group
- 8.2.1 Livzon Group Company Information
- 8.2.2 Livzon Group Business Overview
- 8.2.3 Livzon Group Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Livzon Group Fidaxomicin Product Portfolio
- 8.2.5 Livzon Group Recent Developments
- 8.3 Tecoland
- 8.3.1 Tecoland Company Information
- 8.3.2 Tecoland Business Overview
- 8.3.3 Tecoland Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Tecoland Fidaxomicin Product Portfolio
- 8.3.5 Tecoland Recent Developments
- 8.4 Rochem
- 8.4.1 Rochem Company Information
- 8.4.2 Rochem Business Overview
- 8.4.3 Rochem Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Rochem Fidaxomicin Product Portfolio
- 8.4.5 Rochem Recent Developments
- 8.5 Optimer Pharmaceuticals
- 8.5.1 Optimer Pharmaceuticals Company Information
- 8.5.2 Optimer Pharmaceuticals Business Overview
- 8.5.3 Optimer Pharmaceuticals Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Optimer Pharmaceuticals Fidaxomicin Product Portfolio
- 8.5.5 Optimer Pharmaceuticals Recent Developments
- 8.6 Olon
- 8.6.1 Olon Company Information
- 8.6.2 Olon Business Overview
- 8.6.3 Olon Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Olon Fidaxomicin Product Portfolio
- 8.6.5 Olon Recent Developments
- 8.7 BrightGene Bio-Medical Technology
- 8.7.1 BrightGene Bio-Medical Technology Company Information
- 8.7.2 BrightGene Bio-Medical Technology Business Overview
- 8.7.3 BrightGene Bio-Medical Technology Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 BrightGene Bio-Medical Technology Fidaxomicin Product Portfolio
- 8.7.5 BrightGene Bio-Medical Technology Recent Developments
- 8.8 Astellas
- 8.8.1 Astellas Company Information
- 8.8.2 Astellas Business Overview
- 8.8.3 Astellas Fidaxomicin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Astellas Fidaxomicin Product Portfolio
- 8.8.5 Astellas Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Fidaxomicin Value Chain Analysis
- 9.1.1 Fidaxomicin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Fidaxomicin Production Mode & Process
- 9.2 Fidaxomicin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Fidaxomicin Distributors
- 9.2.3 Fidaxomicin Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst